SUPERNUS PHARMACEUTICALS, INC. Earnings Per Share, Basic and Diluted
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Earnings Per Share, Basic and Diluted of -$0.38 per share for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-13.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2014-05-13
- SUPERNUS PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2014-03-31 was -$0.38.
- SUPERNUS PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2013-12-31 was -$0.65.
- SUPERNUS PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2013-09-30 was -$0.78.
- SUPERNUS PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2013-06-30 was -$0.89.
- SUPERNUS PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2013 was -$2.90.
- SUPERNUS PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2012 was -$2.72, a 108.67% decline from fiscal 2011.
- SUPERNUS PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2011 was $31.39.
- SUPERNUS PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2010 was -$26.38.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2014-03-31 | -$0.38 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | -$0.65 10-K · filed 2014-03-21 | -$1.42 derived: net income ÷ weighted average shares · filed 2017-01-20 | -$2.30 derived: net income ÷ weighted average shares · filed 2017-01-20 | -$2.90 10-K · filed 2014-03-21 |
| 2013-09-30 | -$0.78 10-K · filed 2014-03-21 | -$1.66 derived: net income ÷ weighted average shares · filed 2013-11-13 | -$2.26 10-Q · filed 2013-11-13 | -$2.79 derived: net income ÷ weighted average shares · filed 2015-03-12 |
| 2013-06-30 | -$0.89 10-K · filed 2014-03-21 | -$1.48 10-Q · filed 2013-08-14 | -$2.01 derived: net income ÷ weighted average shares · filed 2015-03-12 | -$2.58 derived: net income ÷ weighted average shares · filed 2015-03-12 |
| 2013-03-31 | -$0.60 10-Q · filed 2014-05-13 | -$1.11 derived: net income ÷ weighted average shares · filed 2015-03-12 | -$1.66 derived: net income ÷ weighted average shares · filed 2015-03-12 | -$2.25 derived: net income ÷ weighted average shares · filed 2015-03-12 |
| 2012-12-31 | -$0.51 10-K · filed 2014-03-21 | -$1.06 derived: net income ÷ weighted average shares · filed 2015-03-12 | -$1.65 derived: net income ÷ weighted average shares · filed 2015-03-12 | -$2.72 10-K · filed 2014-03-21 |
| 2012-09-30 | -$0.55 10-K · filed 2014-03-21 | -$1.15 derived: net income ÷ weighted average shares · filed 2013-11-13 | -$2.36 10-Q · filed 2013-11-13 | $4.23 derived: net income ÷ weighted average shares · filed 2014-03-21 |
| 2012-06-30 | -$0.61 10-K · filed 2014-03-21 | -$2.21 10-Q · filed 2013-08-14 | $9.04 derived: net income ÷ weighted average shares · filed 2014-03-21 | $9.22 derived: net income ÷ weighted average shares · filed 2014-03-21 |
| 2012-03-31 | -$6.05 10-K · filed 2014-03-21 | $42.83 derived: net income ÷ weighted average shares · filed 2014-03-21 | $36.89 derived: net income ÷ weighted average shares · filed 2014-03-21 | |
| 2011-12-31 | $49.51 derived: net income ÷ weighted average shares · filed 2014-03-21 | $43.61 derived: net income ÷ weighted average shares · filed 2014-03-21 | $31.39 10-K · filed 2014-03-21 | |
| 2011-09-30 | -$6.64 10-Q · filed 2012-11-02 | -$19.28 10-Q · filed 2012-11-02 | ||
| 2011-06-30 | -$5.17 10-Q · filed 2012-08-13 | -$12.64 10-Q · filed 2012-08-13 | ||
| 2011-03-31 | -$7.48 10-Q · filed 2012-06-08 | |||
| 2010-12-31 | -$26.38 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |